

REMARKS

In reply to the Office Action dated April 1, 2004, claims 1-7 are currently under examination in the Application. By the above amendment, claims 8-25 have been canceled. Claims 3 and 4 have been amended solely for the purposes of clarity. The above amendment is not to be construed as acquiescence to the stated grounds for objection/rejection and is made without prejudice to prosecution of any subject matter modified and/or removed by this amendment in a related divisional, continuation and/or continuation-in-part application.

Applicants wish to thank the Examiner for noting that claims 1, 2 and 5-7 are allowable.

Information Disclosure Statement

Applicants also wish to thank the Examiner for acknowledgement of the Information Disclosure Statements submitted on February 28, 2002, April 24, 2002 and July 19, 2002. Applicants respectfully request acknowledgement of the Third Supplemental Information Disclosure Statement submitted on **November 5, 2002** and the most recently submitted Fourth Information Disclosure Statement filed **June 28, 2004**.

Claim Objections

The Examiner objects to claim 3 and claim 4 dependent therefrom for informalities. Specifically, the Examiner notes that claim 3 should read "The method" instead of "A method". Applicants thank the Examiner for noting this inadvertent error and have made the appropriate amendment. Applicants respectfully submit that the objection has been overcome and may be properly withdrawn.

Specification

The Examiner notes that the term "CLAIMS" on page 186 is redundant. Applicants have deleted this heading as suggested by the Examiner.

Claims Rejections Under 35 U.S.C. § 112 (Indefiniteness)

Claims 3 and 4 stand rejected for allegedly failing to particularly point out and distinctly claim that which Applicants regard as the invention. Specifically, the Examiner asserts that the limitation "the lung carcinoma polynucleotide" lacks antecedent basis.


Applicants have amended claim 3 as suggested by the Examiner to replace "the lung carcinoma polynucleotide" with "said polynucleotide". Accordingly, Applicants respectfully submit that the rejection has been obviated and may be properly withdrawn.

The Director is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to our Deposit Account No. 19-1090.

Applicants respectfully submit that all the claims remaining in the application are now believed allowable. Favorable consideration and a Notice of Allowance are earnestly solicited.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:tt

Enclosure:

Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031
477468_1.DOC